<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03326232</url>
  </required_header>
  <id_info>
    <org_study_id>17-07-FB-0181</org_study_id>
    <nct_id>NCT03326232</nct_id>
  </id_info>
  <brief_title>Real-time Continuous Glucose Monitoring</brief_title>
  <official_title>Real-time Continuous Glucose Monitoring for the Treatment of Gestational Diabetes: a Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Virginia Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eastern Virginia Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gestational diabetes (GDM) is a condition of carbohydrate intolerance with onset or first
      recognition in pregnancy. The prevalence of GDM is as high as 25% in some populations and
      continues to rise with the increase in obesity and type-2 diabetes. GDM places the pregnancy
      at great risk to both the mother and the neonate. Recent studies have proven that
      interventions including dietary and medications lower the risk to the pregnancy. Both the
      American College of Obstetrics and Gynecology (ACOG) and the American Diabetes Association
      (ADA) recommend dietary interventions with daily glucose monitoring as the initial treatment
      of choice. Meanwhile, outside of pregnancy, promising new technologies such as continuous
      glucose monitors (CGM) are revolutionizing diabetic care. The investigators seek to determine
      if the constant feedback of a real-time CGM system would improve glycemic control compared to
      traditional management in GDM
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators' proposed study will add new information to the emerging use of CGM in
      pregnant women with GDM. First, most studies only use CGM for 48 - 72hours at a time, while
      the investigators will be using CGM for 7 day intervals. Both groups will use the same Enlite
      sensor (Medtronic). The blinded CGM group will be using the Medtronic iPro2 system (Enlite
      sensor + transmitter). The real-time CGM group will be using the 530g system (iPro2 (Enlite
      sensor + transmitter) + inactivated 530g pump set only to display glucose values, no insulin
      will be administered). This CGM system has been FDA approved to for up to 7 days between
      sensor changes.26,27 Second, no previous study has used real time CGM in pregnant patients
      with GDM in the US. The investigators will be the first to describe the use of this
      technology in this patient population. Third, most of these trials have been performed on
      populations that are not representative of the investigators' patient population at EVMS.
      This will be the largest US study of CGM in GDM. Fourth wearable medical and fitness
      technology is already popular, but as both the technology and the demand continues to grow,
      it will become the future of diabetes management. Studies have already shown that real time
      CGM is an effective educational and motivational tool in type-1 and type-2 DM.28,29
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 13, 2017</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean blood glucose (mg/dL)</measure>
    <time_frame>week 1 vs. week 4</time_frame>
    <description>Mean blood glucose (mg/dL) in the real-time CGM group compared to self-monitoring of blood glucose (SMBG) group during the 4th week of study from data collected on the 6 day of CGM use during that week.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Failed dietary therapy</measure>
    <time_frame>week 1 vs. week 4</time_frame>
    <description>Failed dietary therapy (started on medication),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time spent in normoglycemia</measure>
    <time_frame>week 1 vs. week 4</time_frame>
    <description>Time spent in normoglycemia (min/day)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time spent in hypoglycemia</measure>
    <time_frame>week 1 vs. week 4</time_frame>
    <description>Time spent in hypoglycemia (min/day)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI at time of delivery</measure>
    <time_frame>BMI at time of delivery</time_frame>
    <description>BMI at time of delivery (kg/m2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational hypertension</measure>
    <time_frame>enrollement vs delivery.</time_frame>
    <description>Gestational hypertension (defined as systolic blood pressure &gt; 140 mm Hg or diastolic blood pressure &gt; 90 mmg Hg, on 2 occasions at least 4 hrs apart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preeclampsia</measure>
    <time_frame>enrollement vs delivery.</time_frame>
    <description>Preeclampsia (defined as gestational hypertension plus either new-onset proteinuria (&gt; 300 mg/24 2hrs, protein:creatinine &gt; 0.3 mg/dL), thrombocytopenia (platelet count &lt; 100,000/uL), elevated Aspartate aminotransferase or alanine aminotransferase (&gt; 2x upper limit of normal), renal insufficiency (serum creatinine &gt; 1.1 mg/dL or an unexplained doubling of creatinine), pulmonary edema, or cerebral or visual symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1C values</measure>
    <time_frame>HbA1C values week 1 compared to week 4 (%)</time_frame>
    <description>HbA1C values (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polyhydramnios</measure>
    <time_frame>Through study completion, an average of 9 months</time_frame>
    <description>Polyhydramnios (MVP &gt; 8 cm at any point in the pregnancy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cesarean delivery</measure>
    <time_frame>Delivery</time_frame>
    <description>Cesarean delivery (w/ indication: macrosomia, malpresentation, failed induction, fetal distress, failed trial of labor after cesarean, scheduled repeat, other)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction of labor</measure>
    <time_frame>Delivery</time_frame>
    <description>Induction of labor (w/ indication)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative vaginal delivery</measure>
    <time_frame>Delivery</time_frame>
    <description>Operative vaginal delivery (yes/no) and type (forceps/vacuum)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shoulder dystocia</measure>
    <time_frame>Delivery</time_frame>
    <description>Shoulder dystocia (diagnosed clinically)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal macrosomia</measure>
    <time_frame>Most recent ultrasound before delivery</time_frame>
    <description>Fetal macrosomia (&gt; 4,000g at 38 wk u/s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3rd or 4th degree perineal laceration</measure>
    <time_frame>Delivery</time_frame>
    <description>3rd or 4th degree perineal laceration at time of delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational age at delivery</measure>
    <time_frame>Delivery</time_frame>
    <description>Gestational age at delivery (weeks, days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preterm delivery</measure>
    <time_frame>Delivery</time_frame>
    <description>Preterm delivery (&lt; 37 weeks gestational age at birth)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birth weight</measure>
    <time_frame>Delivery</time_frame>
    <description>Birth weight (grams)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perinatal morbidity composite outcome</measure>
    <time_frame>Delivery</time_frame>
    <description>Hypoglycemia (yes/no): &lt; 2 hrs after birth and before feeding, defined as &lt; 35mg/dL
Hyperbilirubinemia (yes/no): collected 16-36 hrs after birth, defined as &gt; 95% for any given point after birth requiring phototherapy according to American Academy of Pediatrics guidelines
Birth trauma (yes/no): brachial plexus injury or clavicular, humeral, or skull fracture
Intrauterine fetal demise or neonatal death (yes/no): prior to hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Large for gestational age</measure>
    <time_frame>Delivery</time_frame>
    <description>Large for gestational age (yes/no): defined as birth weight &gt; 90%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Small for gestational age</measure>
    <time_frame>Delivery</time_frame>
    <description>Small for gestational age (yes/no): defined as birth weight &lt; 10%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admission to neonatal intensive care unit</measure>
    <time_frame>Delivery</time_frame>
    <description>Admission to neonatal intensive care unit (yes/no) and length of neonatal intensive care unit stay (days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory distress syndrome</measure>
    <time_frame>Delivery</time_frame>
    <description>Respiratory distress syndrome (defined as need to supplemental oxygen &gt; 4 hrs after birth)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Gestational Diabetes</condition>
  <arm_group>
    <arm_group_label>Blinded continuous glucose monitoring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The blinded CGM group will be using the Medtronic iPro2 system (Enlite sensor + iPro2 transmitter).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Real time continuous glucose monitoring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The real-time CGM group will be using the 530g system (inactivated 530g insulin pump (no insulin used, only used as display for CGM), Enlite sensor, MiniLink transmitter)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous glucose monitoring</intervention_name>
    <description>The blinded CGM group will be using the Medtronic iPro2 system (Enlite sensor + iPro2 transmitter). The real-time CGM group will be using the 530g system (inactivated 530g insulin pump (no insulin used, only used as display for CGM), Enlite sensor, MiniLink transmitter)</description>
    <arm_group_label>Blinded continuous glucose monitoring</arm_group_label>
    <arm_group_label>Real time continuous glucose monitoring</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  maternal age 18 to 45

          -  singleton gestation

          -  gestational age less than 32 weeks gestation at study inclusion

          -  BMI less than 45

          -  50g glucose challenge greater than 135 mg/dL

          -  100 g 3 hr oral glucose tolerance test greater than 2 abnormal values using the
             Carpenter Coustan cut offs (fasting greater than 95 mg/dL, 1 hr greater than 180
             mg/dL, 2 hr greater than 155 mg/dL, 3 hr greater than 140 mg/dL)

          -  attended the maternal-fetal medicine diabetes education class

        Exclusion Criteria:

          -  maternal age less than18 or greater than 45

          -  multifetal gestation

          -  gestational age greater than 32 weeks study inclusion

          -  BMI greater than 45

          -  pregestational diabetes

          -  gestational diabetes diagnosed before 24 weeks

          -  did not attend the diabetes education class

          -  known fetal anomaly

          -  known fetal aneuploidy

          -  required ongoing treatment with medications that can exacerbate hyperglycemia
             (steroids, hydroxyprogesterone caproate injections (Makena), highly active
             antiretroviral therapy HIV medications)

          -  learning disability

          -  concern for non compliance with medical care

          -  imminent preterm delivery due to maternal disease or fetal conditions

          -  is not willing to wear CGM
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant females with gestational diabetes</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malgorzata Mlynarczyk, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eastern Virginia Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joanne Audouin, MS</last_name>
    <phone>757-446-5121</phone>
    <email>audouij@evms.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrew Lane, MD</last_name>
    <phone>864-608-4134</phone>
    <email>laneas@evms.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Eastern Virginia Medical School</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne Audouin, MS</last_name>
      <phone>757-446-5121</phone>
      <email>audouij@evms.edu</email>
    </contact>
    <contact_backup>
      <last_name>Andrew Lane, MD</last_name>
      <phone>864-608-4134</phone>
      <email>laneas@evms.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Malgorzata Mlynarczyk, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Lane, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margarita de Veciana, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alfred Abuhamad, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Committee on Practice Bulletins--Obstetrics. Practice Bulletin No. 137: Gestational diabetes mellitus. Obstet Gynecol. 2013 Aug;122(2 Pt 1):406-16. doi: 10.1097/01.AOG.0000433006.09219.f1.</citation>
    <PMID>23969827</PMID>
  </reference>
  <reference>
    <citation>Moyer VA; U.S. Preventive Services Task Force. Screening for gestational diabetes mellitus: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014 Mar 18;160(6):414-20. doi: 10.7326/M13-2905.</citation>
    <PMID>24424622</PMID>
  </reference>
  <reference>
    <citation>Correa A, Bardenheier B, Elixhauser A, Geiss LS, Gregg E. Trends in prevalence of diabetes among delivery hospitalizations, United States, 1993-2009. Matern Child Health J. 2015 Mar;19(3):635-42. doi: 10.1007/s10995-014-1553-5.</citation>
    <PMID>24996952</PMID>
  </reference>
  <reference>
    <citation>England LJ, Dietz PM, Njoroge T, Callaghan WM, Bruce C, Buus RM, Williamson DF. Preventing type 2 diabetes: public health implications for women with a history of gestational diabetes mellitus. Am J Obstet Gynecol. 2009 Apr;200(4):365.e1-8. doi: 10.1016/j.ajog.2008.06.031. Epub 2008 Aug 8. Review.</citation>
    <PMID>18691691</PMID>
  </reference>
  <reference>
    <citation>Boney CM, Verma A, Tucker R, Vohr BR. Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics. 2005 Mar;115(3):e290-6.</citation>
    <PMID>15741354</PMID>
  </reference>
  <reference>
    <citation>Malcolm JC, Lawson ML, Gaboury I, Lough G, Keely E. Glucose tolerance of offspring of mother with gestational diabetes mellitus in a low-risk population. Diabet Med. 2006 May;23(5):565-70.</citation>
    <PMID>16681566</PMID>
  </reference>
  <reference>
    <citation>Gillman MW, Rifas-Shiman S, Berkey CS, Field AE, Colditz GA. Maternal gestational diabetes, birth weight, and adolescent obesity. Pediatrics. 2003 Mar;111(3):e221-6.</citation>
    <PMID>12612275</PMID>
  </reference>
  <reference>
    <citation>HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, Hadden DR, McCance DR, Hod M, McIntyre HD, Oats JJ, Persson B, Rogers MS, Sacks DA. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008 May 8;358(19):1991-2002. doi: 10.1056/NEJMoa0707943.</citation>
    <PMID>18463375</PMID>
  </reference>
  <reference>
    <citation>Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS; Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med. 2005 Jun 16;352(24):2477-86. Epub 2005 Jun 12.</citation>
    <PMID>15951574</PMID>
  </reference>
  <reference>
    <citation>Landon MB, Spong CY, Thom E, Carpenter MW, Ramin SM, Casey B, Wapner RJ, Varner MW, Rouse DJ, Thorp JM Jr, Sciscione A, Catalano P, Harper M, Saade G, Lain KY, Sorokin Y, Peaceman AM, Tolosa JE, Anderson GB; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med. 2009 Oct 1;361(14):1339-48. doi: 10.1056/NEJMoa0902430.</citation>
    <PMID>19797280</PMID>
  </reference>
  <reference>
    <citation>Hartling L, Dryden DM, Guthrie A, Muise M, Vandermeer B, Donovan L. Benefits and harms of treating gestational diabetes mellitus: a systematic review and meta-analysis for the U.S. Preventive Services Task Force and the National Institutes of Health Office of Medical Applications of Research. Ann Intern Med. 2013 Jul 16;159(2):123-9. doi: 10.7326/0003-4819-159-2-201307160-00661. Review.</citation>
    <PMID>23712381</PMID>
  </reference>
  <reference>
    <citation>Klonoff DC. Continuous glucose monitoring: roadmap for 21st century diabetes therapy. Diabetes Care. 2005 May;28(5):1231-9. Review.</citation>
    <PMID>15855600</PMID>
  </reference>
  <reference>
    <citation>Mastrototaro J, Shin J, Marcus A, Sulur G; STAR 1 Clinical Trial Investigators. The accuracy and efficacy of real-time continuous glucose monitoring sensor in patients with type 1 diabetes. Diabetes Technol Ther. 2008 Oct;10(5):385-90. doi: 10.1089/dia.2007.0291.</citation>
    <PMID>18715215</PMID>
  </reference>
  <reference>
    <citation>Kestilä KK, Ekblad UU, Rönnemaa T. Continuous glucose monitoring versus self-monitoring of blood glucose in the treatment of gestational diabetes mellitus. Diabetes Res Clin Pract. 2007 Aug;77(2):174-9. Epub 2007 Jan 16.</citation>
    <PMID>17234297</PMID>
  </reference>
  <reference>
    <citation>Murphy HR, Rayman G, Lewis K, Kelly S, Johal B, Duffield K, Fowler D, Campbell PJ, Temple RC. Effectiveness of continuous glucose monitoring in pregnant women with diabetes: randomised clinical trial. BMJ. 2008 Sep 25;337:a1680. doi: 10.1136/bmj.a1680.</citation>
    <PMID>18818254</PMID>
  </reference>
  <reference>
    <citation>Moy FM, Ray A, Buckley BS. Techniques of monitoring blood glucose during pregnancy for women with pre-existing diabetes. Cochrane Database Syst Rev. 2014 Apr 30;(4):CD009613. doi: 10.1002/14651858.CD009613.pub2. Review. Update in: Cochrane Database Syst Rev. 2017 Jun 11;6:CD009613.</citation>
    <PMID>24782359</PMID>
  </reference>
  <reference>
    <citation>de Veciana M, Major CA, Morgan MA, Asrat T, Toohey JS, Lien JM, Evans AT. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med. 1995 Nov 9;333(19):1237-41.</citation>
    <PMID>7565999</PMID>
  </reference>
  <reference>
    <citation>Porter H, Lookinland S, Belfort MA. Evaluation of a new real-time blood continuous glucose monitoring system in pregnant women without gestational diabetes. A pilot study. J Perinat Neonatal Nurs. 2004 Apr-Jun;18(2):93-102.</citation>
    <PMID>15214248</PMID>
  </reference>
  <reference>
    <citation>McLachlan K, Jenkins A, O'Neal D. The role of continuous glucose monitoring in clinical decision-making in diabetes in pregnancy. Aust N Z J Obstet Gynaecol. 2007 Jun;47(3):186-90.</citation>
    <PMID>17550484</PMID>
  </reference>
  <reference>
    <citation>Yu F, Lv L, Liang Z, Wang Y, Wen J, Lin X, Zhou Y, Mai C, Niu J. Continuous glucose monitoring effects on maternal glycemic control and pregnancy outcomes in patients with gestational diabetes mellitus: a prospective cohort study. J Clin Endocrinol Metab. 2014 Dec;99(12):4674-82. doi: 10.1210/jc.2013-4332.</citation>
    <PMID>25057872</PMID>
  </reference>
  <reference>
    <citation>Alfadhli E, Osman E, Basri T. Use of a real time continuous glucose monitoring system as an educational tool for patients with gestational diabetes. Diabetol Metab Syndr. 2016 Jul 26;8:48. doi: 10.1186/s13098-016-0161-5. eCollection 2016.</citation>
    <PMID>27468313</PMID>
  </reference>
  <reference>
    <citation>Głowińska-Olszewska B, Tobiaszewska M, Łuczyński W, Bossowski A. Monthly use of a real-time continuous glucose monitoring system as an educational and motivational tool for poorly controlled type 1 diabetes adolescents. Adv Med Sci. 2013;58(2):344-52. doi: 10.2478/ams-2013-0024.</citation>
    <PMID>23917476</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2017</study_first_submitted>
  <study_first_submitted_qc>October 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2017</study_first_posted>
  <last_update_submitted>November 21, 2017</last_update_submitted>
  <last_update_submitted_qc>November 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes, Gestational</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Do not plan to share.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

